Login
$ORKA
$95.97 +$0.16 (0.17%) Close

Company Executives

Officer Age In this role Joined 2025 pay Source
Lawrence Klein Also a director
President, Chief Executive Officer and Director
43 Not stated Not stated $3,356,050
Laura Sandler
Chief Operating Officer
48 Since 2025
1 year
Not stated Not reported
Joana Goncalves
Chief Medical Officer
52 Not stated 2024 $2,338,593
Paul Quinlan
General Counsel and Corporate Secretary
63 Not stated 2024 $2,338,593
Larry Todd Edwards
Chief Commercial Officer
Title from the Form 4 dated Aug 24, 2026
Not stated Not stated Not stated Not reported
Arjun Agarwal
Senior Vice President, Finance and Treasurer
50 Not stated 2024 Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 5
stated in the proxy; 1 not stated
Average tenure
1.8 years
from year joined
CEO also chairs the board
No
Samarth Kulkarni
Director Age On board Independent Committees Other public boards 2025 pay Source
Samarth Kulkarni
47 2024
2 years
Independent None stated Black Diamond Therapeutics, Inc. $234,067
Lawrence Klein
43 2024
2 years
Not independent None stated None stated Paid as CEO
Carl Dambkowski
41 2024
2 years
Independent None stated None stated $200,567
Peter Harwin
40 2024
2 years
Independent None stated Cogent Biosciences, Inc., Apogee Therapeutics, Inc. $209,067
Chris Martin
50 2025
1 year
Independent None stated Edgewise Therapeutics, Inc. $803,950
Kristine Ball
54 2024
2 years
Not stated None stated None stated $213,067

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 17, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support